
The three sources reviewed here do not provide a matched, head-to-head receptor comparison of cagrilintide and eloralintide. They describe eloralintide cell-based binding and cAMP assays,[1] cagrilintide receptor-complex structures and dynamics,[2] and a separate cagrilintide pharmacology panel.[3] Together, these sources support a comparison of study designs—not a conclusion that either peptide is more potent or selective overall.
A receptor profile depends on the assay
Start with the receptor subtype, species, experimental system, and measured endpoint. The eloralintide paper reports binding and cyclic adenosine monophosphate (cAMP) assays in receptor-expressing cells. The cagrilintide structural paper examines active receptor complexes using cryo-electron microscopy (cryo-EM) and analyzes their dynamics. These measurements answer different questions: receptor interaction, a downstream functional response, and receptor-complex structure are distinct forms of evidence.[1][2]
For a practical comparison, record what each experiment measured before interpreting what its result means. A resolved receptor complex cannot substitute for a functional potency measurement.
What the eloralintide cell assays reported

Briere et al. reported in-vitro binding and cAMP assays in UMUC3 cell lines expressing human or rat AMY1R, AMY3R, or calcitonin receptor (CTR). The paper describes species-dependent receptor profiles. In its human receptor cAMP assays, eloralintide was approximately 12-fold more potent at AMY1R than at CTR and 11-fold more potent at AMY1R than at AMY3R. These are within-study functional comparisons under the reported conditions, not binding-affinity ratios or comparisons with cagrilintide.[1]
| Study element | Reported evidence | Interpretation limit |
|---|---|---|
| Receptor systems | UMUC3 cells expressing human or rat AMY1R, AMY3R, or CTR.[1] | Keep the species and receptor subtype attached to each result. |
| Assay methods | In-vitro receptor binding and cAMP response assays.[1] | Interpret binding and functional response separately. |
| Human functional comparison | Approximately 12-fold greater AMY1R potency than CTR and 11-fold greater AMY1R potency than AMY3R in the human receptor cAMP assays.[1] | These ratios do not describe rat receptors, binding affinity, or relative potency against cagrilintide. |
For example, consider the reported human AMY1R-versus-CTR cAMP comparison. The known conditions include the UMUC3 background, human receptors, and functional readout. The result supports a relative potency statement within those assays. What is missing for the article’s central comparison is a cagrilintide result obtained in a matched experiment. The 12-fold figure therefore cannot establish how the two peptides compare.[1]
The human ratios should not be transferred to the rat panel. The supplied evidence supports the existence of species-dependent profiles, but does not supply the complete rat results needed for an equivalent numerical comparison.[1]
What cagrilintide structure and receptor-panel studies show

Cao et al. reported cryo-EM structures of cagrilintide bound to active, Gs-coupled AMY1R, AMY2R, AMY3R, and CTR complexes, alongside analyses of receptor-complex dynamics. This is structural and dynamics evidence; it does not provide a matched functional comparison with eloralintide.[2]
The separate Fletcher et al. study concerns AM833, identified as cagrilintide. Its abstract describes 25 endpoints covering receptor binding, activation, and regulation, with six selected calcitonin-family agonist comparators. Eloralintide is not among its comparators. Only the abstract was available in this evidence review, so this article does not reconstruct its full methods or detailed receptor results.[3]
| Evidence set | Receptor system or scope | Readout | What it does not establish |
|---|---|---|---|
| Eloralintide cell panel | Human and rat AMY1R, AMY3R, and CTR expressed in UMUC3 cells | Binding and cAMP response.[1] | Relative potency against cagrilintide in a matched experiment |
| Cagrilintide structural study | Active, Gs-coupled AMY1R, AMY2R, AMY3R, and CTR complexes | Cryo-EM structures and receptor-complex dynamics.[2] | A functional potency or selectivity ranking against eloralintide |
| AM833 pharmacology study | Calcitonin-family receptor pharmacology; six selected comparators, excluding eloralintide | Abstract reports 25 endpoints including binding, activation, and regulation.[3] | A cagrilintide-versus-eloralintide comparison or full methods assessment from the abstract alone |
Why the available evidence does not rank the two peptides
Within this three-source set, there is no matched receptor panel testing both compounds. That is a conclusion about the sources reviewed here, not a claim that such evidence is absent from all published literature.[1][2][3]
When evaluating a proposed head-to-head comparison, check:
- Receptor subtype and species: Are both compounds tested at the same receptor systems?
- Constructs and cell background: Are receptor expression and the cellular setting comparable?
- Assay mode and endpoint: Is the comparison binding against binding, or the same functional readout against itself?
- Experimental conditions: Are exposure conditions, timing, and reference controls reported and compatible?
- Analysis: Are potency estimates, response normalization, and uncertainty assessed using comparable methods?
Use these as comparison criteria, not as a validated experimental protocol. For the present source set, retain the human eloralintide cAMP ratios as within-study findings, the cagrilintide structures as structural evidence, and the AM833 abstract as context for a separate pharmacology panel. None supplies the missing matched experiment.
参考来源
- Briere et al. (2025): Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
- Cao et al. (2025): Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors
- Fletcher et al. (2021): AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists
Related research: Eloralintide vs Cagrilintide: Structure, Selectivity, PK and How to Tell Them Apart (2026); Cagrilintide; Cagrilintide Mechanism of Action; Cagrilintide丨A Long-Acting Amylin Analogue for Receptor Pharmacology and Structural Biology Research.
Related SaiyanMed research notes: for the full structure, selectivity and PK comparison see Eloralintide vs Cagrilintide; molecular background is in What Is Eloralintide; research-grade reference material is listed on the Eloralintide peptide (LY3841136) product page.
Research Use Only Disclaimer
This article is for laboratory and analytical research education only. It is not a validated experimental protocol or medical or veterinary advice, and it provides no guidance for administering research materials to humans or animals.
{“@context”:”https://schema.org”,”@type”:”Article”,”@id”:”https://saiyanmed.com/cagrilintide-vs-eloralintide-receptor-profiles-research-comparisons/#article”,”headline”:”Cagrilintide vs Eloralintide: Receptor Profiles and Research Comparisons”,”description”:”Compare eloralintide receptor assays with cagrilintide structural and pharmacology studies, and learn why these sources cannot establish a direct potency ranking.”,”mainEntityOfPage”:{“@id”:”https://saiyanmed.com/cagrilintide-vs-eloralintide-receptor-profiles-research-comparisons/”},”url”:”https://saiyanmed.com/cagrilintide-vs-eloralintide-receptor-profiles-research-comparisons/”,”image”:{“@type”:”ImageObject”,”@id”:”https://saiyanmed.com/cagrilintide-vs-eloralintide-receptor-profiles-research-comparisons/#primaryimage”,”url”:”https://saiyanmed.com/wp-content/uploads/2026/10/01-hero-13.png”,”contentUrl”:”https://saiyanmed.com/wp-content/uploads/2026/10/01-hero-13.png”},”inLanguage”:”en-US”,”citation”:[“https://pmc.ncbi.nlm.nih.gov/articles/PMC12640043/”,”https://pmc.ncbi.nlm.nih.gov/articles/PMC11982234/”,”https://pubmed.ncbi.nlm.nih.gov/33727283/”]}